IL29 Blocking peptide
Référence BP1709a
Conditionnement : 500ug
Marque : Abcepta
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
IL29 Blocking peptide
Synthetic peptide
| Primary Accession | Q8IU54 |
|---|---|
| Other Accession | NP_742152 |
| Clone Names | 3011302 |
| Gene ID | 282618 |
|---|---|
| Other Names | Interferon lambda-1, IFN-lambda-1, Cytokine Zcyto21, Interleukin-29, IL-29, IFNL1, IL29, ZCYTO21 |
| Target/Specificity | The synthetic peptide sequence used to generate the antibody AP1709a was selected from the N-term region of human IL29. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
| Name | IFNL1 |
|---|---|
| Synonyms | IL29, ZCYTO21 |
| Function | Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression. |
| Cellular Location | Secreted. |
Research Areas
- Peptides
- Blocking Peptides